AVEOAVEO PHARMACEUTICALS, INC.

Nasdaq aveooncology.com


$ 14.99 $ 0.00 (0 %)    

Thursday, 19-Jan-2023 15:59:43 EST
QQQ $ 447.63 $ -1.28 (-0.28 %)
DIA $ 396.98 $ -0.90 (-0.23 %)
SPY $ 525.59 $ -0.33 (-0.06 %)
TLT $ 91.68 $ -0.18 (-0.2 %)
GLD $ 217.88 $ -1.36 (-0.62 %)
$ 15
$ 14.99 x 2,000
$ 15.02 x 2,000
-- - --
$ 3.06 - $ 15.00
247,877
na
519.27M
$ 1.27
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-07-2022 09-30-2022 10-Q
2 08-04-2022 06-30-2022 10-Q
3 05-05-2022 03-31-2022 10-Q
4 03-14-2022 12-31-2021 10-K
5 11-08-2021 09-30-2021 10-Q
6 08-05-2021 06-30-2021 10-Q
7 05-10-2021 03-31-2021 10-Q
8 03-16-2021 12-31-2020 10-K
9 11-09-2020 09-30-2020 10-Q
10 08-10-2020 06-30-2020 10-Q
11 04-30-2020 03-31-2020 10-Q
12 03-16-2020 12-31-2019 10-K
13 11-12-2019 09-30-2019 10-Q
14 08-08-2019 06-30-2019 10-Q
15 05-09-2019 03-31-2019 10-Q
16 03-14-2019 12-31-2018 10-K
17 11-09-2018 09-30-2018 10-Q
18 08-07-2018 06-30-2018 10-Q
19 05-08-2018 03-31-2018 10-Q
20 03-13-2018 12-31-2017 10-K
21 11-07-2017 09-30-2017 10-Q
22 08-09-2017 06-30-2017 10-Q
23 05-04-2017 03-31-2017 10-Q
24 03-22-2017 12-31-2016 10-K
25 11-04-2016 09-30-2016 10-Q
26 08-04-2016 06-30-2016 10-Q
27 05-10-2016 03-31-2016 10-Q
28 03-15-2016 12-31-2015 10-K
29 11-09-2015 09-30-2015 10-Q
30 08-10-2015 06-30-2015 10-Q
31 05-07-2015 03-31-2015 10-Q
32 03-06-2015 12-31-2014 10-K
33 11-05-2014 09-30-2014 10-Q
34 08-11-2014 06-30-2014 10-Q
35 05-07-2014 03-31-2014 10-Q
36 03-13-2014 12-31-2013 10-K
37 11-07-2013 09-30-2013 10-Q
38 08-08-2013 06-30-2013 10-Q
39 05-10-2013 03-31-2013 10-Q
40 03-11-2013 12-31-2012 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 aveo-oncology-form-8-filing-closing-of-the-merger-is-expected-to-occur-on-january-19-2023

On January 17, 2023, the parties received written notice from CFIUS that it had determined that there were no unresolved nation...

 on-jan-17-aveo-oncologys-lg-chem-received-written-notice-from-committee-on-foreign-investment-in-the-us-that-there-were-no-unresolved-national-security-concerns-regarding-transaction--all-required-regulatory-approvals-to-complete-merger-have-now-been-received

As previously disclosed, on October 18, 2022, AVEO Pharmaceuticals, Inc., a Delaware corporation (“AVEO”), entered into an Agre...

 reported-late-thursday-aveo-oncology-stockholders-approve-acquisition-by-lg-chem--aveo-stockholders-will-receive-1500-per-share-in-cash-upon-the-closing-of-the-transaction

AVEO Oncology ("AVEO") (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to deliv...

 aveo-oncology-says-effective-as-of-1159-pm-eastern-time-on-december-1-2022-waiting-period-under-hsr-act-expired-with-respect-to-lg-chem-merger

-SEC Filing

 aveo-pharmaceuticals-granted-us-patent-11504365-use-of-tivozanib-to-treat-subjects-with-refractory-cancer

https://www.scribd.com/document/609450380/Aveo-Patent

 benzingas-top-ratings-upgrades-downgrades-for-november-8-2022

Upgrades

 what-4-analyst-ratings-have-to-say-about-aveo-pharmaceuticals

Within the last quarter, AVEO Pharmaceuticals (NASDAQ:AVEO) has observed the following analyst ratings:

 stifel-downgrades-aveo-pharmaceuticals-to-hold-announces-15-price-target

Stifel analyst Stephen Willey downgrades AVEO Pharmaceuticals (NASDAQ:AVEO) from Buy to Hold and announces $15 price target.

 aveo-pharmaceuticals-q3-eps-009-beats-018-estimate-sales-3045m-beat-2955m-estimate

AVEO Pharmaceuticals (NASDAQ:AVEO) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of ...

 jonestrading-downgrades-aveo-pharmaceuticals-to-hold-announces-15-price-target

JonesTrading analyst Soumit Roy downgrades AVEO Pharmaceuticals (NASDAQ:AVEO) from Buy to Hold and announces $15 price target.

 benzingas-top-ratings-upgrades-downgrades-for-october-24-2022

Upgrades

 us-stock-futures-lower-following-fridays-rally-tesla-in-focus

Pre-open movers U.S. stock futures traded lower in early pre-market trade on Monday after recording sharp gains in the previou...

 svb-leerink-downgrades-aveo-pharmaceuticals-to-market-perform

SVB Leerink analyst Andrew Berens downgrades AVEO Pharmaceuticals (NASDAQ:AVEO) from Outperform to Market Perform.

 benzingas-top-ratings-upgrades-downgrades-for-october-19-2022

Upgrades

 baird-downgrades-aveo-pharmaceuticals-to-neutral-lowers-price-target-to-15

Baird analyst Colleen Kusy downgrades AVEO Pharmaceuticals (NASDAQ:AVEO) from Outperform to Neutral and lowers the price tar...

 why-quoin-pharmaceuticals-shares-jumped-by-more-than-44-here-are-57-biggest-movers-from-yesterday

Gainers COMSovereign Holding Corp. (NASDAQ: COMS) shares jumped 170.1% to close at $0.1194 on Tuesday after gaining 4% on Mo...

 carnival-amazon-iamgold-and-other-big-gainers-from-tuesday

U.S. stocks closed higher on Monday, with the Dow Jones gaining more than 300 points. Here is the list of some big stocks recor...

 crude-oil-drops-over-2-akouos-shares-spike-higher

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 300 points on Tuesday.

 hc-wainwright--co-downgrades-aveo-pharmaceuticals-to-neutral-lowers-price-target-to-15

HC Wainwright & Co. analyst Swayampakula Ramakanth downgrades AVEO Pharmaceuticals (NASDAQ:AVEO) from Buy to Neutral and...

 nasdaq-rises-over-100-points-goldman-sachs-tops-q3-views

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Tuesday.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION